This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Ras homolog family member J (RHOJ)	<p>Studies in mice suggest antagonizing RHOJ could help treat cancer by disrupting the tumor vasculature. In multiple mouse models of solid tumors, <i>Rhoj</i> knockout decreased tumor growth, tumor vascularization and metastasis compared with Rhoj expression. A combination of a VEGF inhibitor and a fibronectin-targeting liposome carrying <i>Rhoj</i>-specific siRNA reduced peri- and intratumor vascularization and growth more potently than either agent alone. Next steps include identifying small molecule RHOJ antagonists.</p> <p>SciBX 7(6); doi:10.1038/scibx.2014.170 Published online Feb. 13, 2014</p>	Patent pending; available for licensing	<p>Kim, C. <i>et al. Cancer Cell</i>; published online Jan. 13, 2014; doi:10.1016/j.ccr.2013.12.010</p> <p>Contact: Gou Young Koh, Korea Advanced Institute of Science and Technology, Daejeon, South Korea e-mail: gykoh@kaist.ac.kr</p> <p>Contact: Akiyoshi Uemura, Kobe University Graduate School of Medicine, Kobe, Japan e-mail: auemura@med.kobe-u.ac.jp</p>